en · de · es · fr · pt
selank-notes.peptides6088.com › Guide › Background And Molecular Identity — Practical Notes

Background And Molecular Identity — Practical Notes

By Editorial Desk · published 2026-02-09 · last reviewed 2026-03-11 · Guide

If you have been reading about GABA-A modulation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-03-11. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Molecular Identity

Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.

Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.

Stability, Handling, and Analytical Control

Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.

Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideTuftsin analogue with a C-terminal Pro-Gly-Pro tail
Amino acid sequenceThr-Lys-Pro-Arg-Pro-Gly-ProAbbreviated TKPRPGP in most catalogues
Molecular massAbout 752 DaValue for the free peptide
SolubilityFreely soluble in waterAqueous solutions are kept cold and used promptly
Typical storage-20 °C, dry, protected from lightApplies to the lyophilised powder before reconstitution

Administration, Testing and Availability

Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.

Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.

Related pages on this site

Mechanism and Evidence Base

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Proposed Mechanisms and Research Endpoints

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Reference notes

There are a number of factors that have been identified to have provoked the independent movements. First, increasing control by the Crown of its overseas empire via the Bourbon Reforms of the mid-eighteenth century introduced changes to the relationship of Spanish Americans to the Crown. The language used to describe the overseas empire shifted from "kingdoms" with independent standing with the crown to "colonies" subordinate to Spain. In an effort to better control the administration and economy of the overseas possessions the Crown reintroduced the practice of appointing outsiders, almost all peninsulars, to the royal offices throughout the empire. This meant that Spanish American elites were thwarted in their expectations and ambitions by the crown's upending of long-standing practices of creole access to office holding. The regalist and secularizing policies of the Bourbon monarchy were aimed at decreasing the power of the Roman Catholic Church. The crown had already expelled the Jesuits in 1767, which saw many creole members of the Society of Jesus go into permanent exile. By limiting the power of the Church, the crown attempted to centralize itself within the institutions of colonial Spanish America. Because of the physical and ideological proximity that the clergy had, they could directly influence and dictate the interactions between populations of colonial Spanish America, either as legal counsel or an advisor; a directness which the crown would need to attempt to create the centralized, colonial state which it wanted to implement.

=== Precursor to iron-sulfur clusters === Cysteine is an important source of sulfide in human metabolism. The sulfide in iron-sulfur clusters and in nitrogenase is extracted from cysteine, which is converted to alanine in the process.

=== Legal status === In October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cibinqo, intended for the treatment of atopic dermatitis. The applicant for this medicinal product is Pfizer Europe MA EEIG. In December 2021, the European Commission approved abrocitinib for the treatment of atopic dermatitis. In January 2022, the US Food and Drug Administration (FDA) approved abrocitinib for adults with moderate-to-severe atopic dermatitis.

At the same time, the need for such a system was becoming increasingly pressing. In 1932, Winston Churchill and his friend, confidant and scientific advisor Frederick Lindemann travelled by car in Europe, where they saw the rapid rebuilding of the German aircraft industry. It was in November of that year that Stanley Baldwin gave his famous speech, stating that "The bomber will always get through". In the early summer of 1934, the RAF carried out large-scale exercises with up to 350 aircraft. The forces were split, with bombers attempting to attack London, while fighters, guided by the Observer Corps, attempted to stop them. The results were dismal. In most cases, the vast majority of the bombers reached their target without ever seeing a fighter. To address the one-sided results, the RAF gave increasingly accurate information to the defenders, eventually telling the observers where and when the attacks would be taking place. Even then, 70 per cent of the bombers reached their targets unhindered. The numbers suggested any targets in the city would be destroyed. Squadron Leader P. R. Burchall summed up the results by noting that "a feeling of defencelessness and dismay, or at all events of uneasiness, has seized the public." In November, Churchill gave a speech on "The threat of Nazi Germany" in which he pointed out that the Royal Navy could not protect Britain from an enemy who attacked by air. Through the early 1930s, a debate raged within British military and political circles about strategic airpower.

=== Types === Inorganic compounds: potassium alum, aluminium hydroxide, aluminium phosphate, calcium phosphate hydroxide Oils: paraffin oil, propolis (only in preclinical studies). Adjuvant 65 (based on peanut oil) was tested in influenza vaccines in the 1970s, but was never released commercially. Freund's incomplete adjuvant is a water-in-oil emulsion, a classical adjuvant. Water-in-oils are generally too reactogenic to be used on humans, however. Squalene is a natural oil made by human bodies. MF59 is a oil-in-water emulsion based on squalene. Bacterial products: killed bacteria of the species Bordetella pertussis, Mycobacterium bovis, toxoids. MPL (Monophosphorylated lipid A) is a modified form of a bacterial lipid A protein that is used in several vaccines. Plant saponins from Quillaia (soap bark tree), soybean and Polygala senega Cytokines: IL-1, IL-2, IL-12 CpG oligonucleotides Combinations: Freund's complete adjuvant (incomplete + dead Mycobacterium), AS01 (combining MPL and Quillaia saponins), Matrix-M (combining Quillaia saponins and two types of fat) Small molecules: TLR7/8 agonists (imidazoquinolines, imidazopyrimidines) Physical methods: radiofrequency heating (only tested in mice), microneedles (only tested in mice)

Sources: en.wikipedia.org

Reference notes

== Preparation == Ethane-1,2-dithiol is made commercially by the reaction of 1,2-dichloroethane with aqueous sodium bisulfide. In the laboratory, it can also be prepared by the action of 1,2-dibromoethane on thiourea followed by hydrolysis.

== Discovery == By the mid-1960s, it had become apparent from pharmacologic studies that opioids were likely to exert their actions at specific receptor sites, and that there were likely to be multiple such sites. Early studies had indicated that opiates appeared to accumulate in the brain. The receptors were first identified as specific molecules through the use of binding studies, in which opiates that had been labeled with radioisotopes were found to bind to brain membrane homogenates. The first such study was published in 1971, using 3H-levorphanol. In 1973, Candace Pert and Solomon H. Snyder published the first detailed binding study of what would turn out to be the μ opioid receptor, using 3H-naloxone. That study has been widely credited as the first definitive finding of an opioid receptor, although two other studies followed shortly after.

In a study by Belicka et al., six sediment cores from two shelf-basin transects in the Chukchi and Beaufort Seas of the Arctic Ocean were examined in order to compare the sources and preservation of organic carbon between the two differing depositional regimes. This study found an unexpected correlation between dinosterol and α-amyrin, which is found in terrestrial plants, in shelf and slope sediments, in particular the Beaufort Shelf, suggesting that dinoflagellates contribute significantly to phytoplankton abundance in areas of seasonal open water. Dinosterol was only observed above the permanent ice pack, suggesting that dinoflagellates are restricted to open waters, which in the Arctic occur near the shallow shelves. Consequently, dinosterol may be a potential indicator of the history of open water conditions.

These peptides result from partial proteolysis of intracellular or extracellular protein precursors performed by several processing enzymes or protease complexes (rennin, kallikreins, calpains, prohormone convertases, proteasomes, endosomes, lysosomes), which convert proteins into peptides, including those with biological activities. The resulting protein fragments of various sizes are either readily degraded into free amino acids, or captured by oligopeptidases, whose peculiar binding and/or catalytic properties allow them to fulfill their physiological roles by trimming inactive peptide precursors leading to their active form, converting bioactive peptides into novel ones., inactivating them, thus restraining the continuous activation of specific receptors, or protecting the newly generated bioactive peptide from further degradation, suggesting a peptide chaperon-like activity. TOP, a ubiquitous cytosolic oligopeptidase, is a remarkable example of how this enzyme could play an essential role in immune defense against cancer cells. It has also been successfully used as a hook to fish novel bioactive peptides from cytosol of cells. The involvement of peptides in cell-cell interactions and in neuropsychiatric, autoimmune, and neurovegetative diseases are waiting for peptidomics and gene silencing approaches, which will expedite the formation of new concepts in an emerging era for oligopeptidases. The participation of oligopeptidases in a number of pathologies has long been reported.

rescue teams were not able to travel to Myanmar because of lack of prompt financing and lack of experienced USAID employees to serve as guides. State Department spokesperson Tammy Bruce said, “I would reject the premise that the sign of success is that we are physically there.” And in fact, a large part of the U.S. effort in previous disasters has been to support local clinics, businesses, and local and international relief organizations. Often, there are secondary crisis(es) from diseases such as cholera which can appear in the days and weeks following a disaster. On April 4, 2025, the U.S. committed an extra $7 million to help with the Myanmar earthquake, thereby increasing its commitment from $2 to $9 million.

Sources: en.wikipedia.org

Notes from published material

The active site is located in a long cleft running parallel with the 3 strand across the lower part of the transpeptidase domain. When carbenicillin binds to penicillin binding protein 3, it forms an acyl-enzyme complex which means the β-lactam is chemically attached to PBP3. The β-lactams are covalently bound to S294 which inactivates the enzyme. Also, the N-terminal end of PBP3 is more flexible, however, the C-terminal part, which contains the enzyme’s active site, is very stable and does not change much. The binding of carbenicillin to the active site increases the enzyme's thermostability with conformational changes. The first carboxylate group in carbenicillin forms hydrogen bonding interactions with S485, T487, and N351. These hydrogen bonding interactions help stabilize the binding between carbenicillin and PBP 3.

The micellar theory of Carl Nägeli was developed from his detailed study of starch granules in 1858. Amorphous substances such as starch and cellulose were proposed to consist of building blocks, packed in a loosely crystalline array to form what he later termed "micelles". Water could penetrate between the micelles, and new micelles could form in the interstices between old micelles. The swelling of starch grains and their growth was described by a molecular-aggregate model, which he also applied to the cellulose of the plant cell wall. The modern usage of 'micelle' refers strictly to lipids, but its original usage clearly extended to other types of biomolecule, and this legacy is reflected to this day in the description of milk as being composed of 'casein micelles'.

Exergonic reactions at these environments could have provided free energy that promoted chemical reactions conducive to prebiotic biomolecules. Nonenzymatic reactions of glycolysis and the pentose phosphate pathway can occur in the presence of ferrous iron at 70 °C, the reactions produce erythrose 4-phosphate, an amino acid precursor and ribose 5-phosphate, a nucleotide precursor. Pyrimidines are shown to be synthesized from the reaction between aspartate and carbamoyl phosphate at 60 °C and in the presence of metals, it is suggested that purines could be synthesized from the catalysis of metals. Adenosine monophosphate are also shown to be synthesized from adenine, monopotassium phosphate or pyrophosphate, and ribose at silica at 70 °C. Reductive amination and transamination reactions catalyzed by alkaline hydrothermal vent mineral and metal ions produce amino acids. Long chain fatty acids can be derived from formic acid or oxalic acid during Fischer-Tropsch-type synthesis. Carbohydrates containing an isoprene skeleton can be synthesized from the formose reaction. Isoprenoids incorporated into fatty acid vesicles can stabilize the vesicles, which are suggested to have driven the divergence of bacterial and archaeal lipids.

== Cast and characters == Shun Oguri as Kenji Okamoto, a police detective who was suspended for allowing his former love interest and reporter, Kyoko access to case documents. His suspension was lifted by the Superintendent General in order to investigate brutal murder on live television program case caused by the Human Vapor, later leads him uncover hidden crimes and conspiracies involving the yakuza, the police and the government. Yū Aoi as Kyoko Kono, a reporter and Kenji's former love interest who received a promotion after reporting on a story using his case files. After witnessing a brutal murder on stage, she joins with Kenji in pursuing the truth. Suzu Hirose as Kaho Fujikawa and Kento Hayashi as Fujita Fujikawa, a pair of sibling livestreamers who run a horror and urban-myth webseries titled "Fujita and Kaho's Terror Zone". Only Fujita appears onscreen during their livestreams, as Kaho is insecure about a birthmark which covers half of her face. Their streams regularly attract only a handful of viewers, much to Fujita's frustrations. Uta as Ren Tsutsumida, the Human Vapor. One of many victims of the White Center's experiments, he vanished for a long time before resurfacing to exact revenge. Yutaka Takenouchi as Yasutoshi Mori, a former yakuza member turned company president, and one of the leaders of the White Center.

== History == Gepirone was developed by Bristol-Myers Squibb in 1986, but was out-licensed to Fabre-Kramer in 1993. The FDA rejected approval for gepirone in 2002 and 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2009. However, in 2012 it once again failed to convince the FDA of its qualities for treating anxiety and depression. In December 2015, the FDA once again gave gepirone a negative review for depression due to concerns of efficacy. However, in March 2016, the FDA reversed its decision and gave gepirone ER a positive review. Gepirone ER was finally approved for the treatment of major depressive disorder in the United States in September 2023. A 2026 scientific paper discussed the FDA's decision process and cricitised the approval and subsequent labeling of the drug.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank chemically?

Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.

How does Selank relate to tuftsin?

Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.

Is Selank an approved medicine?

It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.

How should the powder be stored?

Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.

Network